Atossa Therapeutics, Inc. (ATOS)

Over the past six months, Atossa Therapeutics' stock price has fluctuated, with a decline of 40.23% from November 26, 2024, to November 25, 2025. Key events include participation in the Jefferies Global Healthcare Conference, announcement of positive FDA feedback regarding the (Z)-endoxifen program, presentation at the H.C. Wainwright 27th Annual Global Investment Conference, appointment of Mark Daniel as CFO, presentation at the Maxim Growth Summit, acceptance of abstracts for presentation at the 2025 San Antonio Breast Cancer Symposium, reporting of Third Quarter 2025 Financial Results, and highlighting an opportunity for (Z)-endoxifen in Duchenne Muscular Dystrophy. Despite these developments, the stock has shown a declining tendency.

There is an observed monthly seasonality in Atossa Therapeutics, Inc. (ATOS) stock returns. Historically, buying ATOS stock in April has shown the highest probability of a positive return, while November has demonstrated the lowest probability of a positive return. This seasonality pertains to investor interest and stock performance.

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative medicines in oncology, particularly breast cancer. Their lead drug candidate is oral (Z)-endoxifen, currently in Phase II clinical trials for breast cancer treatment and prevention, with a focus on metastatic breast cancer. The company previously developed COVID-19 drug candidates, including AT-H201 and AT-301.

Atossa Therapeutics, Inc. is headquartered in Seattle, Washington, United States, and primarily conducts its operations and clinical trials within the United States.

Atossa Therapeutics, Inc. generally holds a positive brand reputation among analysts, with a consensus rating of "Strong Buy" and an average price target of $6.25 as of September 22, 2025. This reflects confidence in (Z)-endoxifen and its potential in the breast cancer market.

Atossa Therapeutics, Inc. is owned by a mix of institutional shareholders (approximately 15.00%), company insiders (11.04%), and retail investors (73.96%). Major institutional owners include Vanguard Group Inc and BlackRock, Inc. The largest individual shareholder is Shuchih Chen, and Steven C. Quay is also a significant insider shareholder.